Form 4: Organon & Co. Executive Kirke Weaver Reports Stock Option and Restricted Stock Unit Grant

General Counsel & Corporate Secretary of Organon & Co., Kirke Weaver, reports the acquisition of stock options and restricted stock units.

Summary

• On March 29, 2024, Kirke Weaver, General Counsel & Corporate Secretary of Organon & Co., was granted 95,315 stock options and 23,271 restricted stock units (RSUs).
• The stock options have an exercise price of $18.80 and vest in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027.
• The RSUs represent a contingent right to receive one share of Organon common stock for each RSU and also vest in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027.
• Following the reported transaction, Weaver directly owns 95,315 stock options and 23,271 RSUs.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing regarding executive compensation. It doesn't contain overtly positive or negative information, but the granting of equity can be seen as a positive sign of aligning management with shareholder interests.

Positives

• The grant of stock options and RSUs aligns the executive's interests with those of the shareholders, incentivizing performance and long-term value creation.

Future Outlook

The vesting schedule of the stock options and RSUs extends to March 29, 2027, suggesting a long-term incentive structure for the executive.

Industry Context

Stock option and RSU grants are a common form of executive compensation in publicly traded companies, particularly in the pharmaceutical and healthcare sectors, to align management's interests with shareholder value.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are common in the pharmaceutical industry.
• Companies like Pfizer, Merck, and Johnson & Johnson also utilize similar equity-based compensation to incentivize their executives.
• The specific number of options and RSUs granted would need to be compared to industry benchmarks based on company size, performance, and executive role to determine if it is in line with industry standards.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates